A double-blind randomized placebo-controlled study of Desvenlafaxine for managing vasomotor symptoms in breast cancer survivors
Phase 2
Active, not recruiting
- Conditions
- Vasomotor symptoms
- Registration Number
- TCTR20210326006
- Lead Sponsor
- Khon Kaen University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Women, who were diagnosed breast cancer, have moderate to severe vasomotor symptoms
Exclusion Criteria
1. Allergy to SSRI and SNRI
2. Hormonal treatment within 4 weeks prior
3. History of epilepsy
4. History of myocardial infarction within 6 months prior
5. History of depression, bipolar disease or psychological conditions
6. History of glaucoma or increased intraocular pressure
7. Malabsorption
8. Hypertension
9. Impaired liver or renal disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vasomotor symptoms 7 days, 4 weeks, 12 week Frequency of hot flashes, Greene Climacteric Scale
- Secondary Outcome Measures
Name Time Method Adverse events 12 weeks after treatment Patient reported outcome using a questionnaire interview